Past performance
About Concord Biotech Ltd Concord Biotech Ltd, headquartered in Gujarat, India, is a biopharmaceutical company specializing in the development and manufacturing of fermentation-based APIs, particularly in immuno-suppressants and oncology. Originally established in 1984 as Servomed Pharmaceuticals, it was rebranded in 2001. The company serves over 70 countries, including major regulated markets like the US, Europe, and Japan. Concord Biotech operates three manufacturing facilities in Gujarat, with significant fermentation and formulation capacities.
Since 2016, Concord Biotech has expanded its formulation business into emerging markets and the US, launching products such as Mycophenolate Mofetil Capsules and Mycophenolate Sodium Tablets. The company has a robust R&D focus, with six key fermentation-based immunosuppressant APIs as of March 2022. Concord Biotech continues to grow, evident from their joint venture in Japan and expansion into critical care segments. The company plans to raise capital through an offer for sale of 20,925,652 equity shares.
Performance overview